Detailed Narrative
Q3 & 9M FY26 Performance Overview
Insecticides (India) Limited reported resilient Q3 FY26 performance with 8% revenue growth, primarily volume-led, despite a challenging operating environment. For the nine months ended December 31, 2025, revenue from operations increased by 4.44% to INR 1,714 crores from INR 1,641 crores in the prior year. Gross profit for the nine months improved by 7.27% to INR 546 crores, while EBITDA stood at INR 201 crores and PAT at INR 128 crores, remaining flattish.
Margin Pressure and Outlook
Gross margins moderated in Q3 due to a higher share of B2B sales and limited pricing power, with management noting that maintaining a 35% gross profit level in H2 FY26 will be difficult. EBITDA and PAT were impacted by higher finance and depreciation costs. The company expects Q4 to remain muted with continued margin pressure, but views this as a temporary, not structural, erosion, anticipating profitability improvement in coming periods through a focus on specialty products and operating leverage.
Product Mix and New Product Strategy
The company's product mix in 9M FY26 saw B2C contributing 76% (59% premium, 41% generic), B2B 20%, and exports 4%. A key strategic decision is to increase the premium/specialty product share to 70% from the current 60%, by increasing specialty value rather than reducing generic value. New product launches like SPARCLE, Centran, and Million showed strong traction, and the company plans another 5-6 launches in the upcoming kharif season, with at least 5 scheduled for Q1 FY27, including 1 9(3) product and 2 exclusive products.
Sales Returns and Working Capital Management
The company reported significant sales returns of INR 50 crores in Q3, bringing the total for 9M FY26 to INR 200 crores, which is described as the highest ever for IIL, doubling from the previous year. This was attributed to a market situation where herbicides were particularly affected. The sales returns led to inventory buildup and contributed to higher finance costs, as the company utilized INR 200 crores from the bank, which has now been reduced to INR 150 crores. Management is reworking its strategy to prevent recurrence, focusing on tighter credit limits and periods.
Capacity Expansion and Operational Efficiency
The Dahej plant is expected to be operational by the end of FY26, and Sotanala's formulation activities will commence in the next kharif season. The technical plant at Sotanala is projected to take another year, targeting 2027 for full operation, with its formulation facility starting in Q1 FY27. The technical synthesis at Sotanala is expected to increase power and oil bills by INR 30-40 crores annually. The company is focused on disciplined capital allocation, with capex aimed at capacity creation and maintenance, and improving ROCE/ROE to 6-7% over three years.
Market Conditions and Raw Material Outlook
The market environment remains challenging with subdued demand and uneven recovery across regions and crops. Q4 is expected to see pricing pressure with 5-6% discounts due to preseason offers. Raw material prices, while generally stable, saw some increases in January, and the upcoming Chinese New Year could lead to temporary 3-5% cost increases from China. However, management believes prices are near their bottom and the market is stabilizing, with proactive buying strategies in place.